Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Clinical and Experimental Pathology

• Publication date

  2014-04-15

• Fields of study

  Medicine

• Identifiers
  PMID 24966919PMCID PMC4069896
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.

  2014cited by this paper
• Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: A Randomized Open-Label Trial

  2013cited by this paper
• Medical Therapy in Porotic Patients

  2013cited by this paper
• Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis

  2012cited by this paper
• Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

  2012cited by this paper
• Osteoporosis: now and the future

  2011cited by this paper
• Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

  2011cited by this paper
• A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women.

  2011cited by this paper
• Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.

  2011cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

  2010cited by this paper
• Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

  2010cited by this paper
• Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral

  2010cited by this paper
• New treatment modalities in osteoporosis.

  2010cited by this paper
• Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

  2010influential reference
• Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

  2009cited by this paper
• Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation Mice

  2009cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

  2008cited by this paper
• Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice

  2008cited by this paper
• Emerging applications of anticytokine vaccines

  2008cited by this paper
• Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

  2007cited by this paper
• [Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006].

  2007cited by this paper
• Biology of RANK, RANKL, and osteoprotegerin

  2007cited by this paper
• A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

  2006cited by this paper
• [Prevalence and associated factors of osteoporosis among postmenopausal women in Chuncheon: Hallym Aging Study (HAS)].

  2006cited by this paper
• Quality of life in patients with postmenopausal osteoporosis

  2006cited by this paper
• RANK ligand inhibition with denosumab for the management of osteoporosis

  2006cited by this paper
• Newer drug treatments: their effects on fracture prevention.

  2005cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Protein intake: effects on bone mineral density and the rate of bone loss in elderly women.

  2003cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996influential reference
• Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

  1995cited by this paper

• Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use

  2025influential citation
• Osteoporosis and Fracture Risk in Ovarian Cancer: Beyond the Oncologic Burden

  2025cites this paper
• Adverse drug events of denosumab: Data-mining based on the United States Food and Drug Administration Adverse Event Reporting System database

  2024cites this paper
• Pharmacologic and nonpharmacologic treatment modalities for bone loss in SCI - Proposal for combined approach.

  2023cites this paper
• Sex differences in musculoskeletal injury and disease risks across the lifespan: Are there unique subsets of females at higher risk than males for these conditions at distinct stages of the life cycle?

  2023cites this paper
• Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review

  2023cites this paper
• Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases

  2022cites this paper
• Denosumab and risk of community-acquired pneumonia: A population-based cohort study.

  2022cites this paper
• Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies

  2022cites this paper
• Deprescribing in Older Adults With Cancer and Limited Life Expectancy: An Integrative Review

  2021cites this paper
• Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis

  2021cites this paper
• Should denosumab treatment for osteoporosis be continued indefinitely?

  2021cites this paper
• Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women

  2021cites this paper
• Osteopathy in mild adrenal Cushing's syndrome and Cushing disease.

  2021cites this paper
• Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta‐analysis of randomized controlled trials

  2021cites this paper
• Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials

  2020cites this paper
• Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-analysis.

  2020cites this paper
• Drug treatment strategies for osteoporosis in stroke patients

  2020cites this paper
• Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion

  2020cites this paper
• The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women.

  2020cites this paper
• Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

  2019influential citation
• The Role of Dot1l in Prenatal and Postnatal Murine Chondrocytes and Trabecular Bone

  2019cites this paper
• Особливості кальцієво-фосфорного обміну й стану кісток у хворих на ревматоїдний артрит: патоґенез, діаґностика та принципи диференційованого лікування

  2019cites this paper
• Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.

  2019cites this paper
• Biophysical Regulation of Stem Cell Osteogenic Lineage Commitment: A Role for the Cytoskeleton

  2019cites this paper
• Peculiarities of Calcium-Phosphorus Metabolism and Bone State in Patients with Rheumatoid Arthritis: Pathogenesis, Diagnosis and Principles of Differential Treatment (Literature Review and Clinical Case Description)

  2019cites this paper
• DDDT_A_148654 2843..2852

  2019influential citation
• Universitet Antibody-based inhibition of circulating DLK 1 protects from estrogen deficiency-induced bone loss in mice

  2018cites this paper
• Antibody-based inhibition of circulating DLK1 protects from estrogen deficiency-induced bone loss in mice.

  2018cites this paper
• Clinical Management of Osteoporotic Fractures

  2018cites this paper
• The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease

  2018cites this paper
• Osteoporosis: Diagnosis and Management

  2018cites this paper
• Current Knowledge, Drug-Based Therapeutic Options and Future Directions in Managing Osteoporosis

  2017cites this paper
• DOES BALANCE IMPROVE AFTER THE APPLICATION OF TAI CHI EXERCISE PROGRAM IN POST- MENOPAUSAL WOMEN WITH OSTEOPOROSIS?

  2017cites this paper
• Osteoporosis: a discussion on the past 5 years

  2017cites this paper
• Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis

  2017cites this paper
• Increased CD14+ and decreased CD14− populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients

  2017cites this paper
• [Algal oligosaccharides ameliorate osteoporosis via up-regulation of parathyroid hormone 1-84 and vascular endothelial growth factor].

  2016cites this paper
• Algal oligosaccharides ameliorate osteoporosis via up-regulation of parathyroid hormone 1-84 and vascular endothelial growth factor

  2016cites this paper
• Application of TLC-Densitometry for Analysis of Estradiol Hemihydrate in Dosage Forms.

  2016cites this paper
• Safety issues and adverse reactions with osteoporosis management

  2016cites this paper
• Baltic Sport Science Society Sport and Health Baltic Journal of Sciences

  2016cites this paper
• Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention

  2016cites this paper
• Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: a randomized intervention trial

  2016cites this paper
• The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women

  2015cites this paper
• Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.

  2015cites this paper
• Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies

  2015cites this paper
• Osteonecrosis of the jaws.

  2015cites this paper
• Osteonecrosis of alveolar mandibular bone in the patient treated with dental implants due to application of antiresorptive madication. A case report

  2015cites this paper
• A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.

  2015cites this paper
• Prevention and treatment of bone fragility in cancer patient.

  2015cites this paper